Study Design, Setting, and Participants
This prospective case series was performed at the University of
Pennsylvania following Institutional Review Board approval. Patients
were eligible for this study if they were >18 years old and
undergoing TORS resection of a biopsy-proven p16-positive OPSCCC with or
without neck dissection between February 2016 and January 2018. All
patients provided informed consent. Patients with a history of
radiation, chemotherapy, or recurrent malignancy were excluded.